Biklin (Amikacin)

What Is Biklin and What Is It Used For?

Amikacin is a semisynthetic derivative of kanamycin A, first developed in the 1970s as a response to the growing problem of bacterial resistance to existing aminoglycoside antibiotics. Unlike many other aminoglycosides, amikacin is resistant to the majority of aminoglycoside-modifying enzymes produced by bacteria, which makes it particularly effective against multidrug-resistant gram-negative organisms. This resistance profile has made it an indispensable tool in modern infectious disease management, especially in intensive care settings.

Biklin works by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria, interfering with the initiation complex between messenger RNA and the ribosome. This process disrupts bacterial protein synthesis, leads to misreading of the genetic code, and ultimately causes cell death. Amikacin demonstrates concentration-dependent bactericidal activity, meaning that higher peak concentrations relative to the minimum inhibitory concentration (MIC) of the pathogen result in more effective bacterial killing.

The primary clinical indications for Biklin include severe infections caused by aerobic gram-negative bacteria, particularly when other aminoglycosides have proven ineffective or when resistance is suspected. Specific conditions where amikacin is commonly prescribed include:

• Severe urinary tract infections (UTIs): Including complicated pyelonephritis and catheter-associated urinary tract infections caused by resistant organisms such as Pseudomonas aeruginosa, Escherichia coli, Proteus, Providencia, Klebsiella, and Serratia species.
• Respiratory tract infections: Including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), particularly those caused by multidrug-resistant Pseudomonas aeruginosa or Acinetobacter baumannii.
• Septicemia (bloodstream infections): Amikacin is frequently used as part of empiric therapy for sepsis, often in combination with a beta-lactam antibiotic, pending culture and sensitivity results.
• Intra-abdominal infections: Including peritonitis and abdominal abscess, typically in combination with other agents providing anaerobic coverage.
• Bone and joint infections: Including osteomyelitis and septic arthritis caused by susceptible gram-negative organisms.
• Skin and soft tissue infections: Including surgical wound infections and burns complicated by gram-negative bacterial superinfection.
• Central nervous system infections: Including meningitis caused by gram-negative bacilli, though penetration into cerebrospinal fluid is limited.
• Mycobacterial infections: Amikacin is used as part of multidrug regimens for the treatment of infections caused by nontuberculous mycobacteria (NTM), particularly Mycobacterium avium complex (MAC) and Mycobacterium abscessus.

Amikacin covers a broad spectrum of aerobic gram-negative bacteria. Key organisms in its spectrum of activity include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, Acinetobacter species, Providencia stuartii, Citrobacter freundii, and many strains of Proteus. It also has activity against Staphylococcus aureus, although it is not typically used as monotherapy for staphylococcal infections. Importantly, amikacin retains activity against many gentamicin-resistant and tobramycin-resistant organisms, making it a vital reserve antibiotic.

What Should You Know Before Taking Biklin?

Aminoglycoside antibiotics including amikacin have a well-documented potential for causing serious adverse effects, particularly to the kidneys and the auditory/vestibular system. Before initiating treatment with Biklin, healthcare providers must carefully weigh the severity of the infection against the potential risks, and conduct a thorough assessment of the patient's medical history, current medications, and baseline organ function.

Contraindications

Biklin should not be used in patients with known hypersensitivity to amikacin, any other aminoglycoside antibiotic, or any of the excipients in the formulation. Cross-sensitivity between aminoglycosides has been documented, meaning patients allergic to gentamicin, tobramycin, netilmicin, or streptomycin may also react to amikacin. Additionally, amikacin should generally be avoided in the following situations:

• Myasthenia gravis: Aminoglycosides can exacerbate neuromuscular weakness and should be used with extreme caution or avoided entirely in patients with this condition.
• Pre-existing severe renal impairment: While dose adjustments can be made for mild to moderate renal impairment, severe kidney dysfunction significantly increases the risk of drug accumulation and toxicity.
• Concurrent use of other nephrotoxic or ototoxic agents: The combination of amikacin with other drugs that damage the kidneys or hearing (such as cisplatin, vancomycin, or loop diuretics) greatly increases the risk of irreversible damage.

Warnings and Precautions

Several important warnings and precautions should be observed during amikacin therapy. Nephrotoxicity is one of the most clinically significant concerns. Amikacin accumulates in the proximal tubular cells of the kidneys, where it can cause acute tubular necrosis. Risk factors for nephrotoxicity include advanced age, pre-existing renal impairment, dehydration, prolonged treatment courses (exceeding 10 days), high total cumulative doses, and concurrent administration of other nephrotoxic drugs. Kidney function should be assessed before treatment begins and monitored regularly throughout the course, typically by measuring serum creatinine and estimated glomerular filtration rate (eGFR).

Ototoxicity is the other major concern. Amikacin can damage both the cochlear (hearing) and vestibular (balance) divisions of the eighth cranial nerve. Cochlear toxicity typically presents as high-frequency hearing loss, which may progress to lower frequencies and become clinically apparent. Vestibular toxicity can manifest as dizziness, vertigo, ataxia, and nystagmus. Unlike nephrotoxicity, ototoxicity is frequently irreversible. Risk factors include prolonged treatment, high cumulative doses, pre-existing hearing impairment, and concurrent use of other ototoxic drugs such as loop diuretics, cisplatin, or other aminoglycosides. Audiometric testing should be performed before and during treatment in patients receiving prolonged courses.

Neuromuscular blockade is a rare but potentially life-threatening complication. Aminoglycosides can inhibit neuromuscular transmission, leading to respiratory paralysis, particularly in patients who are also receiving neuromuscular blocking agents, who have myasthenia gravis, or who are experiencing hypocalcemia. Calcium salts may help reverse aminoglycoside-induced neuromuscular blockade.

Pregnancy and Breastfeeding

Amikacin should only be used during pregnancy when the potential benefit clearly justifies the potential risk to the fetus. Aminoglycoside antibiotics as a class are known to cross the placenta and have been associated with irreversible bilateral congenital deafness in children whose mothers received aminoglycosides (particularly streptomycin) during pregnancy. While direct evidence of fetal ototoxicity specifically from amikacin is limited, the class effect warrants extreme caution. If amikacin must be used during pregnancy, the lowest effective dose should be employed for the shortest possible duration, with close monitoring of both mother and fetus.

Amikacin is excreted in breast milk in small quantities. However, aminoglycosides are poorly absorbed from the gastrointestinal tract, so systemic exposure to the nursing infant is expected to be minimal. Nevertheless, the potential for disruption of the infant's intestinal flora and the theoretical risk of sensitization should be considered. The prescribing physician should weigh the benefits of breastfeeding and the mother's need for amikacin treatment when making this decision.

How Does Biklin Interact with Other Drugs?

Drug interactions involving amikacin are primarily related to its potential for nephrotoxicity, ototoxicity, and neuromuscular blockade. Healthcare providers must carefully review all concurrent medications before initiating amikacin therapy and monitor patients closely for signs of toxicity when co-administration is unavoidable. The following table summarizes the most clinically significant drug interactions:

Major Interactions

Minor Interactions

In addition to the major interactions listed above, several other clinically relevant interactions should be noted. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac can reduce renal blood flow and potentially increase amikacin serum levels, particularly in patients with pre-existing renal impairment. Oral anticoagulants such as warfarin may have their effects altered by aminoglycoside therapy, as the disruption of intestinal flora can reduce vitamin K production, potentially enhancing the anticoagulant effect.

Beta-lactam antibiotics (penicillins and cephalosporins) may inactivate aminoglycosides when mixed in the same IV solution, though this interaction is not clinically significant when the drugs are administered separately. Patients receiving concomitant parenteral nutrition containing calcium or magnesium should have their amikacin administered through a separate IV line to prevent physicochemical incompatibility.

What Is the Correct Dosage of Biklin?

Amikacin dosing requires careful individualization based on the patient's weight, renal function, severity and site of infection, and serum drug level monitoring. Modern clinical practice increasingly favors once-daily (extended-interval) dosing for most indications, as this approach maximizes the concentration-dependent bactericidal effect of aminoglycosides while potentially reducing the risk of nephrotoxicity and ototoxicity by allowing longer drug-free intervals.

Adults

Children

Pediatric dosing of amikacin requires special consideration due to differences in pharmacokinetics compared to adults. Children generally have a larger volume of distribution per kilogram of body weight, which means they may require relatively higher mg/kg doses to achieve therapeutic serum concentrations. For children over 1 month of age, the recommended dose is 15–22.5 mg/kg/day given as a single daily IV infusion. Neonates, particularly premature infants, have immature renal function and require extended dosing intervals (every 24–48 hours depending on gestational and postnatal age) and careful monitoring of serum drug levels.

The pediatric infectious disease team should be consulted whenever possible for dosing guidance in neonates and young infants, as pharmacokinetic variability is substantial in this population. Weight-based dosing should use actual body weight unless the child is significantly overweight, in which case an adjusted body weight calculation may be more appropriate.

Elderly

Elderly patients are at increased risk of both nephrotoxicity and ototoxicity due to age-related decline in renal function. Even when serum creatinine appears normal, the glomerular filtration rate (GFR) may be significantly reduced in older adults due to decreased muscle mass. Dosing should be based on estimated creatinine clearance (e.g., using the Cockcroft-Gault equation) rather than serum creatinine alone. Lower doses and/or extended dosing intervals are frequently necessary. Therapeutic drug monitoring is essential, and baseline audiometric testing should be performed before initiating treatment.

Missed Dose

Since amikacin is administered in a clinical setting under medical supervision, missed doses should be managed by the healthcare team. If a dose is delayed or missed, it should be administered as soon as possible, with subsequent doses adjusted based on the new timing and serum drug level results. The dosing schedule should not be compressed by giving two doses close together, as this increases the risk of toxicity without providing additional therapeutic benefit.

Overdose

Overdose of amikacin may result in nephrotoxicity, ototoxicity, and neuromuscular blockade. In cases of acute overdose, the drug can be removed from the blood by hemodialysis, which is particularly effective due to amikacin's relatively small molecular weight and minimal protein binding. Peritoneal dialysis is less effective. Supportive care should include maintenance of adequate hydration, monitoring of renal function, audiometric assessment, and respiratory support if neuromuscular blockade occurs. Calcium gluconate may be administered to help reverse neuromuscular blockade.

What Are the Side Effects of Biklin?

Like all aminoglycoside antibiotics, amikacin carries a significant risk of adverse effects, most notably affecting the kidneys and the auditory/vestibular system. The incidence and severity of side effects are closely related to the total cumulative dose, duration of therapy, serum drug levels (particularly trough levels), and the patient's underlying risk factors. Proper therapeutic drug monitoring and adherence to recommended dosing guidelines can substantially reduce the risk of serious adverse events.

The following frequency-based classification of side effects is based on published literature, postmarketing surveillance data, and international pharmacovigilance reports:

It is important to note that nephrotoxicity from aminoglycosides is usually reversible if detected early through routine monitoring of serum creatinine and drug levels. The kidneys can typically regenerate damaged tubular cells once the drug is discontinued. However, ototoxicity is frequently irreversible because the sensory hair cells of the cochlea and vestibular apparatus do not regenerate. This distinction underscores the importance of proactive monitoring, particularly audiometric testing, during treatment courses longer than 5–7 days.

How Should You Store Biklin?

Biklin solution for injection should be stored at controlled room temperature between 15°C and 25°C (59°F to 77°F). The product should be protected from light and should not be frozen, as freezing can alter the physicochemical properties of the solution and potentially affect its potency and sterility. Amikacin solutions may develop a pale yellow color over time; this does not indicate a loss of potency, and the product may still be used if no particulate matter is visible and the solution remains clear.

Once the vial is opened, the solution should be used promptly. If diluted for intravenous infusion, the diluted solution should be used within 24 hours when stored at room temperature or within 48 hours when refrigerated at 2–8°C (36–46°F), unless otherwise specified by the manufacturer. Any unused solution remaining after the recommended storage time should be discarded appropriately. As with all injectable medications, the solution should be inspected visually for particulate matter and discoloration prior to administration.

Patients should not attempt to store or self-administer amikacin at home unless specifically trained and authorized by their healthcare provider as part of an outpatient parenteral antibiotic therapy (OPAT) program. In such cases, patients receive detailed instructions on proper storage, preparation, and administration techniques from specialized pharmacists and nurses.

What Does Biklin Contain?

The active substance in Biklin is amikacin, present as amikacin sulfate. Each milliliter of the solution for injection contains amikacin sulfate equivalent to 250 mg of amikacin base. Amikacin sulfate is a white to off-white crystalline powder that is freely soluble in water. The molecular formula is C₂₂H₄₃N₅O₁₃ · 2H₂SO₄, with a molecular weight of approximately 781.76 g/mol for the sulfate salt.

The inactive ingredients (excipients) typically include:

• Sodium citrate: Acts as a buffering agent to maintain the pH of the solution within the optimal range for stability and tolerability.
• Sodium metabisulfite: An antioxidant preservative. Patients with sulfite sensitivity should be aware of this excipient, as it may cause allergic-type reactions including anaphylaxis and severe asthmatic episodes in susceptible individuals.
• Sulfuric acid and/or sodium hydroxide: Used for pH adjustment to bring the solution to its target pH (typically 3.5–5.5).
• Water for injection: The solvent vehicle for the formulation.